Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
XB-ART-2879
Nat Genet. November 1, 2004; 36 (11): 1213-8.

Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis.

Hellemans J , Preobrazhenska O , Willaert A , Debeer P , Verdonk PC , Costa T , Janssens K , Menten B , Van Roy N , Vermeulen SJ , Savarirayan R , Van Hul W , Vanhoenacker F , Huylebroeck D , De Paepe A , Naeyaert JM , Vandesompele J , Speleman F , Verschueren K , Coucke PJ , Mortier GR .


Abstract
Osteopoikilosis, Buschke-Ollendorff syndrome (BOS) and melorheostosis are disorders characterized by increased bone density. The occurrence of one or more of these phenotypes in the same individual or family suggests that these entities might be allelic. We collected data from three families in which affected individuals had osteopoikilosis with or without manifestations of BOS or melorheostosis. A genome-wide linkage analysis in these families, followed by the identification of a microdeletion in an unrelated individual with these diseases, allowed us to map the gene that is mutated in osteopoikilosis. All the affected individuals that we investigated were heterozygous with respect to a loss-of-function mutation in LEMD3 (also called MAN1), which encodes an inner nuclear membrane protein. A somatic mutation in the second allele of LEMD3 could not be identified in fibroblasts from affected skin of an individual with BOS and an individual with melorheostosis. XMAN1, the Xenopus laevis ortholog, antagonizes BMP signaling during embryogenesis. In this study, LEMD3 interacted with BMP and activin-TGFbeta receptor-activated Smads and antagonized both signaling pathways in human cells.

PubMed ID: 15489854
Article link: Nat Genet.

Genes referenced: lemd3 tgfb1
Antibodies referenced:

My Xenbase: [ Log-in / Register ]
version: [3.2.2]


Major funding for Xenbase is provided by the National Institute of Child Health and Human Development, grant P41 HD064556